Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 07, 2005. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, authorized by shareholders at the Annual General Meeting on May 25, 2005.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 1,250,000 ordinary shares.
- Purchase Price: 1,445.92 pence per share.
- Total Treasury Shares Held: 131,858,000 shares following the transaction.
- Shares in Issue: 5,829,838,528 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program. The company purchased 1,250,000 shares on December 07, 2005, and intends to hold them in Treasury. This action increases the total number of Treasury shares held by the company to 131,858,000.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase or subscribe for securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the repurchase by multiplying 1,250,000 shares by 1,445.92 pence.
- Confirm the updated share capital structure (5,829,838,528 shares in issue) against subsequent filings.
- Review the Annual General Meeting minutes from May 25, 2005, to understand the full scope of the share buyback authorization.
- Note that this filing does not contain operational or financial performance data for the period.